C-kit expression in uterine leiomyosarcomas: An immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus

Journal of Chemotherapy

Volumn 15, Issue 1, 2003, Pages 81-84

  Raspollini, M R ^a   Villanucci, A ^a   Amunni, G ^a   Paglierani, M ^a   Taddei, A ^a   Taddei, Gian Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antigen CD117; c kit; Chemotherapy; Imatinib (STI571); Uterine leiomyosarcomas

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GROWTH FACTOR RECEPTOR; IFOSFAMIDE; IMATINIB; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; METASTASIS; MUSCLE CANCER; ONCOGENE C KIT; PROGNOSIS; RECURRENT DISEASE; UTERUS SARCOMA;

EID: 0242669308     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.1.81     Document Type: Article

References (17)

1. Dimetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001; 28 (suppl 17): 19-26.
2. Heinrich M, Griffith D J, Druker B J, Wait C L, Ott K A, Zigler A J. Inhibition of C-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932.
3. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001; 33: 451-455.
4. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, immunohistochemical and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24 (10): 1339-1352.
5. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990; 63: 185-194.
6. Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors. A study of 27 cases. Arch Pathol Lab Med 2000; 124: 1471-1475.
7. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-4300.
8. Joensuu H, Robert P J, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344 (14): 1052-1056.
9. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-23.
10. Mayerhofer K, Obermairn A, Windbichler G, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999; 74: 196-201.
11. De Vita VT, Hellman S, Rosemberg SA. Cancer, Principles and Practice of Oncology. 5th Edition, Lippincott - Raven, Philadelphia - New York, 1997: 333-347
12. Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996; 62 (1): 25-32.
13. De Paco G, Stefanon B, Raspaglieli F. Neoplasie del corpo dell'utero in Bonadonna G, Robustelli della Cuna G. Medicina oncologica. (6th edition), Masson, Milano-Paris-Barcellona, 1999.
14. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
15. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Eng J Med 2001; 344: 1038-1042.
16. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutation in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53-60.
17. Lux ML, Rubin BP, Biase TL, et al. Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-795.